The European House – Ambrosetti and Sofinnova Partners announce the hosting of BioEquity Europe 2022 in Milan, Italy
For the first time, this event, which has been bringing together leading global VCs and biotech startups for over 20 years will be hosted in Milan.
Milan, Italy, October 1, 2020
The European House - Ambrosetti and Sofinnova Partners are pleased to announce that the city of Milan has been selected to host BioEquity Europe in 2022. BioEquity Europe is one of the most important events on the continent for leading global venture capital investors and startups in the European biopharmaceutical industry. The announcement was made at a press conference held today at the Milano Innovation District (MIND).
With this initiative, The European House – Ambrosetti and Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, are once again supporting the potential of the Italian life sciences ecosystem and working to secure new opportunities for growth.
After months of working toward taking the Italian life sciences ecosystem to a higher level and building a network of biotech excellence and scientific expertise in the territory, we are thrilled to announce that the 2022 edition of BioEquity Europe will take place in Milan.
"These have been very intense months of meetings and exchanges for the enhancement of the candidacy, which have involved the Italian life sciences community, together with many of the main actors of the national scientific research and innovation ecosystem, representatives of institutions, and important players in research and academia, business and finance.
It is with great pride that today, we can announce that our candidacy has been very successful, and that Italy will host BioEquity Europe 2022 for the first time,” said Valerio De Molli, Managing Partner and CEO, The European House – Ambrosetti. “This result shows us, once again, how essential it is to work together and network on a national level. We are now starting a new phase of the path, which will see us engaged in preparing the national life sciences ecosystem to leverage this great opportunity and build an increasingly strong presence for Italy in the European life sciences panorama.
“We are proud to have played a pivotal role in bringing this seminal event to Milan,” said Graziano Seghezzi, Managing Partner, Sofinnova Partners. “BioEquity is an important reference in the biotech industry. The selection of Milan as the host of the 2022 edition is an important milestone for Italian biotech and a further demonstration of Sofinnova Partners’ commitment to contributing to the ongoing growth of a thriving biotech ecosystem in Italy.”
The organisers of BioEquity Europe are pleased to bring our important international forum to Milan. The Regional Host, led by The European House - Ambrosetti, has made an excellent choice for Milan's entry into the BioEquity community. We look forward to contributing to making Milan an important innovation ecosystem and making it visible to the global community of life science innovators and investors," said David Flores, Co-founder, President and CEO of BioCentury.
This historic achievement came to fruition thanks to the support of the Promoter Committee that we set up to support the candidacy.
We would like to thank:
Angelino Alfano (President, San Donato Hospital Group; former Minister of Foreign Affairs
and International Cooperation; former Minister of the Interior; former Minister of Justice)
Matteo Bonfanti (Technology Transfer Director, Italian Institute of Technology)
Elena Bottinelli (Chief Executive Officer, IRCCS San Raffaele Hospital and IRCCS Galeazzi
Diana Bracco (President, Bracco; President, Cluster Alisei - Life Sciences Italian Cluster)
Luigi Boggio (Representative of the industrial stakeholders, Cluster Alisei; Member of the Board, Wise Srl)
Roberta Cocco (Councilor Digital Transformation and Civic Services, Municipality of Milan)
Lorenzo Wittum (Chief Executive Officer, AstraZeneca Italy)
Elena Zambon (President, Zambon)
The press conference was held in the framework of the sixth edition of the Technology Forum Life Sciences, which aired from September 29 to October 1. Following the press conference, the closing session of the Forum was held on "The future of Biotech", with the participation of Andrew Hessel (President, Humane Genomics Inc), Graziano Seghezzi (Managing Partner, Sofinnova Partners), Francesca Pasinelli (General Manager, Fondazione Telethon), Gabriella Camboni (CEO, BiovelocITA), Alessio Beverina (Secretary, VC Hub; Founder & General Partner, Panakes Partners) and Valerio De Molli (Managing Partner and CEO, The European House - Ambrosetti).
The Life Sciences Community is the reference platform of The European House - Ambrosetti for topics related to research and innovation in Life Sciences in Italy.
Founded in 2015, the Life Sciences Community is active with the mission to "contribute to the enhancement of research and innovation in the Life Sciences sector in Italy, promoting centers of excellence and networking national stakeholders to promote the transfer of knowledge, development of new projects and improve the positioning and competitiveness of the country system at the international level".
The Life Sciences Community operates with the intent to be a multi-stakeholder platform - where industrial, institutional, research, university and financial actors can interact on a common level - and aims to:
Identify the challenges and opportunities for research and innovation in the Life Sciences sector in Italy;
Enhance national excellence and increase awareness of the importance of investment in research and innovation in the country;
Strengthen the direct interaction between institutions, national and regional policy makers, academia, the world of research, business and finance;
Elaborate proposals and projects and to promote their implementation and concretization;
Ppromote activities and initiatives of Technology Transfer in Life Sciences.
The European House - Ambrosetti is a group of about 260 professionals active since 1965, which has grown significantly over the years thanks to the contribution of many Partners, with numerous activities in Italy, Europe and around the world. The Group has five offices in Italy and several foreign offices, as well as other partnerships around the world. Its strong expertise is the ability to support companies in the integrated and synergistic management of the four critical dynamics of value generation processes: Watch, Design, Realize and Valorize. For more than 50 years alongside Italian companies, every year we served about 1,000 clients in the Consulting field, carrying out more than 100 Studies and Strategic Scenarios addressed to national and European Institutions and companies and about 100 projects for entrepreneurial families. To these numbers are added about 2,000 national and international experts who each year are involved in the 300 events for over 10,000 managers accompanied in their growth paths. The Group benefits from an invaluable heritage of international relations at the highest level in the various sectors of activity, including the heads of the main international institutions and individual countries. For the seventh consecutive year, The European House - Ambrosetti was also named in 2020 - in the category "Best Private Think Tanks" - 1st Think Tank in Italy, among the top 10 in Europe and among the most respected independent in the world out of 8,248 globally in the last edition of the "Global Go To Think Tanks Report" of the University of Pennsylvania, through a survey addressed to 70,000 leaders of companies, institutions and media, in over 100 countries worldwide. For more information, visit www.ambrosetti.eu and follow us on Twitter https://twitter.com/Ambrosetti_.
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, London and Milan, the firm brings together a team of over 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed 500 companies over 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com